12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Uplyso alfataliglicerase regulatory update

Protalix said the Mexican Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) and the Public Health Institute of Chile approved Uplyso alfataliglicerase for long-term enzyme replacement therapy in adults with Type I Gaucher's disease. In May 2012, FDA...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >